Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults

• Main Authors: Suvimol Niyomnaitham (Author), Zheng Quan Toh (Author), Patimaporn Wongprompitak (Author), Laddawan Jansarikit (Author), Kanjana Srisutthisamphan (Author), Sompong Sapsutthipas (Author), Yuparat Jantraphakorn (Author), Natthakarn Mingngamsup (Author), Paul V Licciardi (Author), Kulkanya Chokephaibulkit (Author)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

We evaluated the immunogenicity and reactogenicity of heterologous COVID-19 primary schedules involving BNT162b2 (Pfizer-BioNTech), ChAdOx1 nCoV-19 (AstraZeneca) and CoronaVac (Sinovac) in healthy adults, as well as booster response to BNT162b2 following heterologous CoronaVac and ChAdOx1 nCoV-19 re...